Boundless Bio (BOLD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 15, 2026, via live webcast for stockholders of record as of April 20, 2026.
Proxy materials, including the Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online and by request in paper or email format.
Voting matters and shareholder proposals
Stockholders will vote on the election of two director nominees: James Christensen, Ph.D., and Jennifer Lew.
Proposal to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board recommends a vote for each director nominee and for the auditor ratification proposal.
Additional business may be transacted as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board of directors includes nominees James Christensen, Ph.D., and Jennifer Lew, up for election at the annual meeting.
Latest events from Boundless Bio
- ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers.BOLD
Corporate presentation8 May 2026 - Q1 2026 net loss narrowed to $13.6M; cash runway and KOMODO-1 trial support BBI-940 progress.BOLD
Q1 20268 May 2026 - Stockholders will vote on director elections and auditor ratification, with strong governance in place.BOLD
Proxy filing28 Apr 2026 - Phase I trial launched for a novel oral degrader targeting ecDNA-driven breast cancers.BOLD
Leerink Global Healthcare Conference 202611 Mar 2026 - First-in-class Kinesin degrader BBI-940 targets ecDNA-driven cancers with early clinical progress.BOLD
Corporate presentation9 Mar 2026 - KOMODO-1 trial advances as focus shifts to BBI-940, with cash runway into late 2028.BOLD
Q4 20259 Mar 2026 - Phase 1 trial of BBI-940, an ecDNA-targeting degrader, is now enrolling breast cancer patients.BOLD
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Advancing ecDNA-targeted cancer therapies with strong leadership, robust pipeline, and solid funding.BOLD
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Precision oncology programs target ecDNA-driven resistance, with pivotal data expected in 2025.BOLD
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026